Each pharmacy shall notify the board of pharmacy immediately upon knowledge of the termination of the services of the pharmacist-in-charge and further, shall immediately designate a successor pharmacist-in-charge and notify the board of pharmacy of such designation.
The board of pharmacy upon receiving such notice shall furnish the successor pharmacist-in-charge with all necessary forms required to be completed by the successor pharmacist-in-charge. Such forms shall be completed and filed with the board within ten days after receipt.
Which of the statement(s) is/are NOT TRUE under the Rhode Island State Pharmacy Law?
I. When a change of ownership of services is contemplated, the owner shall notify the Department in writing at least 14 days prior to the proposed action.
II. When discontinuation of services is contemplated, the owner shall notify the Department in writing at least 30 days prior to the proposed action.
III. When a pharmacist-in-charge of a pharmacy services is terminated, the owner shall notify the Department in writing at least 72-hour prior to the proposed action.
a. I only
b. I and II only
c. II and III only
d. All
Which of the statement(s) is/are NOT TRUE under the Rhode Island State Pharmacy Law?
I. When a change of ownership of services is contemplated, the owner shall notify the Department in writing at least 14 days prior to the proposed action.
II. When discontinuation of services is contemplated, the owner shall notify the Department in writing at least 30 days prior to the proposed action.
III. When a pharmacist-in-charge of a pharmacy services is terminated, the owner shall notify the Department in writing at least 72-hour prior to the proposed action.
a. I only
b. I and II only
c. II and III only
d. All
Answer: II and III are NOT TRUE, [Rules and Regulations Pertaining to Pharmacists, Pharmacies and Manufacturers, Wholesalers and Distributors - Part II Section 12].
12.1 When a change of ownership or location or when discontinuation of services is contemplated, the owner shall notify the Department in writing at least fourteen (14) days prior to the proposed action.
12.2 The pharmacy owner shall give the Department fourteen (14) days' notice in writing prior to terminating services of a pharmacist-in-charge of a pharmacy, unless the pharmacist-incharge vacates the position without notice. In this instance, the Department shall be notified in writing immediately of the change in pharmacist-in-charge.
12.3 When there is a change in ownership and/or location, the license shall immediately become void and shall be delivered to the Department.
12.3.1 The Board, or its designee, reserves the right to extend the expiration date of such license, allowing the pharmacy to operate, but under conditions stipulated by the Board for such time as shall be required for the processing of a new application.
12.3.2 The new applications must be filed accompanied by the initial licensure fee.
12.4 Any renovations or remodeling of an existing pharmacy shall not be considered a change of location.
12.5 Patient records shall be retained and shall be capable of being retrieved for no less than two (2) years after a change of ownership is completed.
Which of the following shall be placed on the label of multi-drug single-dosing container?
I. The name of the prescribing practitioner of each drug.
II. The name, strength, exact physical description, and total quantity of each drug contained therein.
III. The identifying serial number assigned to the prescription drug order for each drug contained therein.
a. I only
b. I and II only
c. II and III only
d. All
Which of the following shall be placed on the label of multi-drug single-dosing container?
I. The name of the prescribing practitioner of each drug.
II. The name, strength, exact physical description, and total quantity of each drug contained therein.
III. The identifying serial number assigned to the prescription drug order for each drug contained therein.
a. I only
b. I and II only
c. II and III only
d. All
Answer: All, [Rules and Regulations Pertaining to Pharmacists, Pharmacies and Manufacturers, Wholesalers and Distributors - Part II Section 8.3.6].
8.3.6 Each individual, customized, multi-drug single-dosing container shall bear a label, which, at a minimum, contains the following:
(a). The name of the patient;
(b). The name of the prescribing practitioner of each drug;
(c). The identifying serial number assigned to the prescription drug order for each drug contained therein;
(d). The name, strength, exact physical description, and total quantity of each drug contained therein;
(e). The directions for use, and/or time of administration or time to be taken for each individual multi-drug single-dosing container;
(f). Either the dispensing or preparation date, as well as a beyond-use (expiration) date for each drug contained in the multi-drug single-dosing container. The expiration date of each drug included therein shall not be longer than one (1) year from the date of preparation of the multi-drug single-dosing container. All drugs shall be packaged in accordance with USP standards.
8.3.7 The name, address, and telephone number of the pharmacy issuing the multi-drug single dosing container and any cautionary statements necessary for the proper administration or storage of the medication shall appear on the individualized patient container.
The cryogenic vessel shall be properly labeled and color coded according to the medical gas contained in the vessel. Which of the following color-code is used for medical oxygen?
a. Yellow
b. Green
c. Gray
d. Brown
The cryogenic vessel shall be properly labeled and color coded according to the medical gas contained in the vessel. Which of the following color-code is used for medical oxygen?
a. Yellow
b. Green
c. Gray
d. Brown
Answer:Green. As used in this section, "cryogenic vessel" means an insulated metal container in the form of a cylinder or other design used to hold gases that have been liquefied by extreme reductions in temperature.
(C). Each cryogenic vessel subject to this section shall meet the following requirements:
(1). The vessel shall be properly labeled according to the medical gas contained in the vessel.
(2). The vessel shall be color coded as follows:
(a). Air - yellow;
(b). Carbon dioxide - gray;
(c). Cyclopropane - orange;
(d). Helium - brown;
(e). Nitrogen - black;
(f). Nitrous oxide - blue;
(g). Oxygen - green. The colors specified in this division shall not be used for any medical gas other than those specified in this division.
INTERPOL has issued a global alert for a drug knows as 2.4-dinitrophenol (DNP), an illicit and potentially lethal drug sold as a dieting and body-building aid.
The “Orange Notice” (PDF) warning about DNP was published after a woman in the United Kingdom died and a man in France was left seriously ill after taking the substance.
In the 1930s, DNP was used to boost metabolism and encourage weight loss, but it was taken out of circulation due to several deaths. Sold as a plain yellow powder, capsules, or cream, DNP is often illegally manufactured and sold via the Internet; unsafe manufacturing of the drug and potential contamination may be magnifying the dangers of taking the drug, notes INTERPOL.
INTERPOL has issued a global alert for a drug knows as 2.4-dinitrophenol (DNP), an illicit and potentially lethal drug sold as a dieting and body-building aid.
The “Orange Notice” (PDF) warning about DNP was published after a woman in the United Kingdom died and a man in France was left seriously ill after taking the substance.
In the 1930s, DNP was used to boost metabolism and encourage weight loss, but it was taken out of circulation due to several deaths. Sold as a plain yellow powder, capsules, or cream, DNP is often illegally manufactured and sold via the Internet; unsafe manufacturing of the drug and potential contamination may be magnifying the dangers of taking the drug, notes INTERPOL.
The prescriber shall obtain the written consent for the OPIOID prescription from the minor's parent, guardian, or, another adult authorized to consent to the minor's medical treatment. This form is commonly known as:
a. "Start Talking!"
b. "Minor Opioid"
c. "Opioid Consequences"
d. “Minor Consent”
The prescriber shall obtain the written consent for the OPIOID prescription from the minor's parent, guardian, or, another adult authorized to consent to the minor's medical treatment. This form is commonly known as:
a. "Start Talking!"
b. "Minor Opioid"
c. "Opioid Consequences"
d. “Minor Consent”
(1). As part of the prescriber's examination of the minor, assess whether the minor has ever suffered, or is currently suffering, from mental health or substance abuse disorders and whether the minor has taken or is currently taking prescription drugs for treatment of those disorders;
(2). Discuss with the minor and the minor's parent, guardian, or another adult authorized to consent to the minor's medical treatment all of the following:
(a). The risks of addiction and overdose associated with the compound;
(b). The increased risk of addiction to controlled substances of individuals suffering from both mental and substance abuse disorders;
(c). The dangers of taking controlled substances containing opioids with benzodiazepines, alcohol, or other central nervous system depressants;
(d). Any other information in the patient counseling information section of the labeling for the compound required under 21 C.F.R. 201.57(c)(18).
(3). Obtain written consent for the prescription from the minor's parent, guardian, or, subject to division (E) of this section, another adult authorized to consent to the minor's medical treatment.
The prescriber shall record the consent on a form, which shall be known as the "Start Talking!" consent form. The form shall be separate from any other document the prescriber uses to obtain informed consent for other treatment provided to the minor. The form shall contain all of the following:
(a). The name and quantity of the compound being prescribed and the amount of the initial dose;
(b). A statement indicating that a controlled substance is a drug or other substance that the United States drug enforcement administration has identified as having a potential for abuse;
(c). A statement certifying that the prescriber discussed with the minor and the minor's parent, guardian, or another adult authorized to consent to the minor's medical treatment the matters described in division (B)(2) of this section;
(d). The number of refills, if any, authorized by the prescription;
(e). The signature of the minor's parent, guardian, or another adult authorized to consent to the minor's medical treatment and the date of signing.
Pharmacists in California may now provide naloxone, the medication that can help to reverse the effects of an opioid overdose, without a prescription after the California State Board of Pharmacy approved new emergency regulations (PDF).
To be eligible to dispense the drug under the new regulations, pharmacists must complete one hour of continuing education (CE) on the use of the drug, notes a press release (PDF) from the Board.
When dispensing the drug, pharmacists must screen for any hypersensitivity, and must provide the recipient with training in opioid overdose prevention, recognition, response, and on the administration of the drug.
The pharmacist must also provide the recipient a naloxone fact sheet (PDF), which has been approved by the Board.
In October 2014, NABP released a statement supporting an active role for pharmacists in increasing access to naloxone.
NABP is also active in educating consumers about prescription drug abuse and prevention through the AWARXE® Prescription Drug Safety Program, and information and educational resources on these topics are available on the program’s website.
Pharmacists in California may now provide naloxone, the medication that can help to reverse the effects of an opioid overdose, without a prescription after the California State Board of Pharmacy approved new emergency regulations (PDF).
To be eligible to dispense the drug under the new regulations, pharmacists must complete one hour of continuing education (CE) on the use of the drug, notes a press release (PDF) from the Board.
When dispensing the drug, pharmacists must screen for any hypersensitivity, and must provide the recipient with training in opioid overdose prevention, recognition, response, and on the administration of the drug.
The pharmacist must also provide the recipient a naloxone fact sheet (PDF), which has been approved by the Board.
In October 2014, NABP released a statement supporting an active role for pharmacists in increasing access to naloxone.
NABP is also active in educating consumers about prescription drug abuse and prevention through the AWARXE® Prescription Drug Safety Program, and information and educational resources on these topics are available on the program’s website.
II. A separate identifying serial number for each of the prescription orders for each of the drug products contained therein.
III. The name, address, and telephone number of the dispenser.
a. I only
b. I and II only
c. II and III only
d. All
The patient med pak shall bear a label stating:
I. A serial number for the patient med pak.
II. A separate identifying serial number for each of the prescription orders for each of the drug products contained therein.
III. The name, address, and telephone number of the dispenser.
a. I only
b. I and II only
c. II and III only
d. All
Answer: All, [Title 20 Code of State Regulations (CSR) 2220-2.145(2)(A)].
(A). The patient med pak shall bear a label stating—
1. The name of the patient;
2. A serial number for the patient med pak itself and a separate identifying serial number for each of the prescription orders for each of the drug products contained therein;
3. The name, strength, physical description or identification and total quantity of each drug product contained therein;
4. The directions for use and cautionary statements if any, contained in the prescription order for each drug product therein;
5. Any storage instructions or cautionary statements required by the official compendia;
6. The name of the prescriber of each drug product;
7. The date of preparation of the patient med pak and the beyond-use date assigned to the patient med pak (such beyond-use date shall be not later than sixty (60) days from the date of preparation);
8. The name, address, and telephone number of the dispenser; and
9. Any other information, statements, or warnings required for any of the drug products contained therein.
The terms "prescription" and "drug order" do not include an order for medication requiring a prescription to be dispensed, which is provided for the immediate administration to the ultimate user or recipient.
True or False
The terms "prescription" and "drug order" do not include an order for medication requiring a prescription to be dispensed, which is provided for the immediate administration to the ultimate user or recipient.
True or False
Answer: True. The terms "prescription" and "drug order" do not include an order for medication requiring a prescription to be dispensed, which is provided for the immediate administration to the ultimate user or recipient.
It shall be unlawful for any person to retail any poisons enumerated in schedules "A" that CONTAIN:
I. arsenic and its preparations
II. biniodide of mercury
III. cyanide of potassium
a. I only
b. I and II only
c. All
d. None of the above
It shall be unlawful for any person to retail any poisons enumerated in schedules "A" that CONTAIN:
I. arsenic and its preparations
II. biniodide of mercury
III. cyanide of potassium
a. I only
b. I and II only
c. All
d. None of the above
Answer: None of the above - all choices can be sold at retail, [Missouri Revised Statutes (MRS) Chapter 338 Sections 338.090].
It shall be unlawful for any person to retail any poisons enumerated in schedules "A" and "B", EXCEPT AS FOLLOWS:
Schedule "A" arsenic and its preparations, biniodide of mercury, cyanide of potassium, hydrocyanic acid, strychnia, and all other poisonous vegetable alkaloids and their salts, and the essential oil of bitter almonds.
Schedule "B" opium and its preparations, except paregoric and other preparations of opium containing less than two grains to the ounce, aconite, bella donna, colchicum, conium, nux vomica, henbane, savin, ergot, cotton root, cantharides, creosote, veratrum, digitalis, and their pharmaceutical preparations, croton oil, chloroform, chloral hydrate, sulphate of zinc, corrosive sublimate, red precipitate, white precipitate, mineral acids, carbolic acid, oxalic acid, without labeling the box, vessel or paper in which the said poison is contained, and also the outside wrapper or cover with the name of the article, the word "poison" and the name and place of business of the seller.
Nor shall it be lawful for any person to sell or deliver any poisons enumerated in schedules "A" and "B" unless, upon due inquiry, it is found that the purchaser is aware of its poisonous character and represents that it is to be used for legitimate purposes.
Nor shall it be lawful for any registered pharmacists to sell any poisons included in schedule "A" without, before delivering the same to the purchaser, causing an entry to be made in a book kept for that purpose, stating
a. the date of sale, name and address of purchaser,
b. the name of the poison sold,
c. the purpose for which it was represented by the purchaser to be required and
d. the name of the dispenser.
Such book to be always open for inspection by the proper authorities, and to be preserved for at least five years.
The provisions of this section shall not apply to the dispensing of poison in not unusual quantities or doses upon the prescription of practitioners of medicine.
